Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Drug Profile

Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Alternative Names: Anti-IL21; NN-8828; NN-9828; NNC-0114-0000-0005; NNC0114-0006; NNC114-0005

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Interleukin 21 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2015 Phase-II clinical trials in Type-1 diabetes mellitus (Combination therapy, Newly diagnosed) in Denmark, United Kingdom, Sweden, Ukraine, Spain, Serbia, Russia, Portugal, Italy, Israel, Norway, Ireland, Finland, Austria, Canada, USA (IV)
  • 23 May 2015 Novo Nordisk plans a phase II trial for Type-I diabetes mellitus (Newly diagnosed, Combination therapy) in USA, Austria, Canada, Denmark, Finland, Ireland, Israel, Italy, Norway, Portugal, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom (NCT02443155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top